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took and what additional evidence was requested. Data on 19 projects that entered 
phase III and 30 products achieving first world approval from 2009-2012 were ana-
lysed. Results: For the phase III projects, 63% received HTA scientific advice, of 
which 61% occurred during phase II, with company-sponsored advisory boards 
the being most frequent provider. The main HTA-related requirements included 
in development were patient-reported outcomes (84%), HTA-acceptable endpoints 
(74%), and cost-effectiveness analysis (74%). For licensed products, the median 
time from regulatory submission to reimbursement decision varied from 639 days 
(Australia) to 846 days (Italy). Additional comparators for local HTA submission were 
requested by all jurisdictions except USA. England and France showed the highest 
percentage of products being reimbursed as per the regulatory label (50% and 55% 
respectively). ConClusions: Companies are actively taking scientific advice and 
incorporating HTA requirements into their development process, although they are 
still challenged by divergence in HTA process and decision making across jurisdic-
tions. Benchmarking HTA processes at the product level supports companies in 
driving excellence in risk management and strategic planning.
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objeCtives: The special committee of cost-effectiveness at the Japanese health 
ministry advisory panel was established in 2012 and the need for economic evalu-
ation guidelines was proposed. The research team funded by the Japanese Ministry 
of Health, Labour and Welfare published the guidelines for economic evaluation of 
health care technologies in 2013. We compared the Japanese guidelines to existing 
guidelines in other Asian countries and to the NICE guidelines (UK). Methods: We 
searched for and reviewed the Japanese research report and guidelines published 
in China, Taiwan, Thailand and South Korea up to February 2014. Similarities and 
differences between Japanese guidelines and those from other Asian countries as 
well as NICE guidelines were identified. Results: Pharmacoeconomic evaluations 
are mandatory in the UK, South Korea and Thailand, recommended in Taiwan, and 
optional in China. In Japan, economic evaluations are currently not formally consid-
ered in pricing and reimbursement decisions. Japanese guidelines are relatively open, 
leaving much room for decision from analysts. Guidelines from different countries 
were broadly consistent in terms of preferred analytical technique (cost-effectiveness 
analysis), need of systematic reviews of evidence and consideration of effectiveness 
data as well as efficacy; but varied in terms of primary perspective for estimating costs 
(third-party payer in Japan), preferred outcome measure (no systematic use of QALYs 
in Japan, other measures, such as laboratory values, also accepted), preferred methods 
to derive utility values (generic instruments with scoring algorithm developed in 
Japan), and sensitivity analysis methods (probabilistic sensitivity analysis “when pos-
sible”). ConClusions: This comparative exercise provides an overview of economic 
evaluation guidelines adopted by 5 Asian countries and UK. The recommendations 
differed in some aspects, but Japanese guidelines are relatively open, which should 
facilitate adaptations of models between countries. One of the hurdles for adapting 
models is likely to be the variability in approaches recommended to obtain utilities.
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objeCtives: A rapid growth of health technology assessment (HTA) activities 
among researchers and physicians in Japan is observed since the mid-1980s. 
However, Japan lags behind Europe, Australia, and several Asian countries in imple-
menting national HTA regulations. Although it is generally accepted that low health 
care costs and good health prevail in Japan, population aging, rising costs of medical 
technologies and slow economic growth rates necessitate rethinking the current 
HTA regulations. This study aims to evaluate the history and current situation of 
the Japanese HTA system, and what Japan needs to do in order to successfully 
implement national HTA regulations. Methods: Past and current Japanese HTA 
regulation are assessed by analysing both English and Japanese publications and 
legal documents, as well as comparing these with the systems in other Asia-Pacific 
countries: Australia, South Korea, Taiwan, Thailand. Results: There are historical, 
social, and biological reasons why Japan has been successful at maintaining the 
world’s longest life expectancy and the lowest infant mortality at relatively low cost 
despite the lack of a comprehensive HTA system. However, implementation of HTA 
regulation would be a key lever in the health system in line with the new economic 
policy introduced by Prime Minister Abe in 2012. Looking at the legal and organisa-
tional structures, implementation and performance of Asia-Pacific HTA systems, 
a comprehensive HTA system for Japan is proposed. ConClusions: HTA systems 
have been rapidly developing in the Asia-Pacific over the last decade. Facing the 
current pressures on the health system, the question is not whether Japan should 
introduce a comprehensive HTA system but what measures she should adopt. The 
experience of other Asia-Pacific countries in implementing national HTA systems 
can help inform the development of an innovative national HTA system in Japan 
that could play a central role in the future of Japanese health care.
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dations by these is likely to be influenced by factors other than process taxon-
omy. ConClusions: This study identified the greatest level of congruence for HTA 
recommendations from the A taxonomy agencies. Other factors likely play a role in 
the divergences of reimbursement recommendations among dissimilar taxonomies, 
which could be better understood by refining the HTA taxonomy characteristics.
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objeCtives: Da Vinci Surgical System (DVSS) is the most widely studied surgical 
robot in recently years, which is developed to assist surgeons performing surgical 
procedures. However, DVSS is associated with high capital and operating costs. 
Given its limitations, a review of clinical and economic evidence is necessary for 
decision-makers. we conducted a rapid review to evaluate the clinical and cost-
effectiveness of DVSS compared with open procedures and laparoscopic procedures, 
in order to provide the evidence for health decision makers. Methods: A compre-
hensive search of electronic databases (EMBASE, PubMed, Cochrane Library, Web of 
Science, CINAHL, CNKI, VIP, CBM and Wangfang) and HTA websites were completed 
to October 9, 2013. Two trained reviews independently screened for eligible studies, 
extracted data and assessed quality. Qualitative description was used to report the 
outcomes. Results: After an initial screen of 272 studies, 18 studies (n= 45,516) 
were selected for meeting inclusion criteria: 3 studies with 32,499 patients were 
healthy technology assessments and 15 studies with 13,017 patients were system-
atic reviews. The clinical and cost-effectiveness of DVSS was varied between dis-
eases. Overall, DVSS was shown to be associated with a reduction in operative time, 
length of hospital stay, blood loss, and transfusion rate compared with open and 
laparoscopic surgery on prostatetomy, nephrectomy, and hysterectomy colorectal 
surgery. DVSS was more expensive than open and laparoscopic surgery for the cost 
of acquiring, operating, and maintaining the robotic techniques. Most economic 
studies showed no significant difference was found in cost- effectiveness of DVSS 
comparing with comparators. ConClusions: DVSS may have an impact on several 
clinical outcomes. However, the evidence was limited to systematic review and 
healthy technology assessments. Furthermore, the cost of DVSS is higher than open 
and laparoscopic surgery. Taking all of this evidence together, decisions about the 
robot-assisted surgery need to be made carefully.
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objeCtives: Local pharmacoeconomic evidence was seldom included in the manu-
facturers’ new drugs submission in Taiwan before. A series of pragmatic strategies 
were employed to encourage the presentation of local cost-effectiveness analysis 
(CEA) evidence in the dossiers. This study aims at examing the performance of these 
strategies. Methods: An incentive of mark-up for conducting local CEA studies has 
been announced since 2010 to encourage the pharmaceutical manufacturers to sub-
mit CEA evidence for new drugs reimbursement application. The National Institute of 
Health Technology Assessment (NIHTA) has started to use a self-developed checklist 
to assess the quality of the local CEA evidence presented in the dossiers. The appraisal 
committee would then decide the extent of mark-up based on the assessment results. 
Three epochs were defined as (1) before mark-up epoch: 2008-2009 (No Mark-up 
Epoch), (2) mark-up without checklist epoch: 2010-the mid-2012 (No Checklist Epoch), 
and (3) mark-up with checklist epoch (Checklist Epoch): mid-2012 till 2013. The num-
ber and the quality of local CEA evidence identified from the dossiers submitted by 
the manufacturers in the three epochs were compared. Results: In the No Mark-up 
epoch, none local CEA evidence has been presented in the dossiers. However, 5 and 
7 local CEA studies have been identified from the dossiers in the Mark-up epoch and 
the Checklist epoch, respectively. None out of the 5 local CEA studies has received the 
mark-up, nevertheless, 6 out of the 7 local CEA studies have receive 1% to 5% mark-
up for the reimbursement price. ConClusions: The pragmatic strategy seems an 
effective approach to encourage the manufacturers to present local CEA evidence in 
the dossiers, which could improve the quality of decision making. In addition, the 
capacity of conducting local CEA studies has been gradually established.
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objeCtives: To evaluate the impact of HTA on the development and market access 
of new pharmaceutical products in Australia, Canada, England, France, Germany, 
Italy, Spain and the USA. Methods: An annual benchmarking study was devel-
oped in collaboration with 9 multinational pharmaceutical companies to establish 
appropriate developmental performance metrics to identify if scientific advice 
was received, when it was received, from whom and the outcome and specific 
HTA requirements included into the development process. In addition data were 
also collected across 8 jurisdictions (Australia, Canada, England, France, Germany, 
Italy, Spain and the USA) to identify what evidence was submitted, the time it 
